Welcome to our dedicated page for Axsome Therapeutics SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Axsome Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Axsome Therapeutics's regulatory disclosures and financial reporting.
Axsome Therapeutics Chief Financial Officer Nick Pizzie reported an option exercise and related share sale. On January 22, 2026, he exercised stock options for 12,000 shares of common stock at an exercise price of $3.5 per share that were originally granted in 2019 and were due to expire in 2028. The filing notes this exercise was made under a pre-approved 10b5-1 trading plan.
The same day, he sold 12,000 shares of Axsome common stock in open-market transactions at a weighted average sale price of $187.92 per share, with individual sale prices ranging from $185.09 to $191.12. After these transactions, he directly beneficially owns 42,588 shares of common stock and holds an additional 488 shares indirectly as custodian for his children's UTMA accounts, along with 105,000 stock options beneficially owned following the reported exercise.
Axsome Therapeutics Chief Commercial Officer Ari Maizel reports an option exercise and share sale. On January 21, 2026, he exercised a stock option for 7,500 shares of common stock at an exercise price of $70.73 per share. The same day, he sold 7,500 shares of common stock in open-market transactions at a weighted average price of $184.44 per share, fully disposing of the acquired shares.
The filing notes that these transactions were made under a pre-approved Rule 10b5-1 trading plan, which is designed to allow preset trading of shares. Following the option transaction, Maizel beneficially owns 31,210 stock options directly, with no common shares reported as directly owned after the sale.
Axsome Therapeutics, Inc. filed a notice of proposed insider sale of 12,000 common shares under Rule 144. The shares are to be sold through Charles Schwab & Co., Inc. on NASDAQ, with an aggregate market value of 2,254,989.00. The filing notes that there were 50,412,640 common shares outstanding at the time of the notice.
The 12,000 shares were acquired on 01/22/2026 through an employee stock option exercise from Axsome Therapeutics, Inc. The exercise was structured as a broker-facilitated cashless exercise, meaning the broker handled payment in connection with the transaction. The person on whose behalf the sale is planned represents that they are not aware of any material adverse, nonpublic information about the company’s operations.
Axsome Therapeutics, Inc. has a planned sale of 7,500 shares of common stock, according to a Form 144 notice. The shares are to be sold through Charles Schwab & Co., Inc. on the NASDAQ, with an aggregate market value of $1,383,327.00. The filing lists total common shares outstanding as 50,412,640.
The 7,500 shares were acquired on 01/21/2026 via an employee stock option exercise from Axsome Therapeutics, Inc., using a broker payment for a cashless exercise on the same date. The Form 144 also includes a representation that the seller does not know of any undisclosed material adverse information about the issuer.
Axsome Therapeutics, Inc. filed a Form 8-K to report that it issued a press release titled “Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue.” The company is furnishing the press release as Exhibit 99.1 under Item 2.02, covering results of operations and financial condition, and also referencing it under Item 8.01 as an other event.
The company specifies that the information in Item 2.02, including Exhibit 99.1, is being furnished rather than filed, so it is not subject to liability under Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings unless specifically stated. The exhibit list confirms the press release and the related cover page data file as the primary attachments.
Axsome Therapeutics insider activity shows CEO Herriot Tabuteau exercising stock options and selling the resulting shares under a pre-approved Rule 10b5-1 trading plan. On January 5, 2026, he exercised 78,703 options at $8.02 per share and sold 78,703 common shares at a weighted average price of $171.28. On January 6, 2026, he exercised 29,450 options at $8.02 and sold 29,450 shares at a weighted average price of $172.33. On January 7, 2026, he exercised 31,261 options at $8.02 and sold 31,261 shares at a weighted average price of $170.38. After these trades, he directly owns 7,229 common shares and is the indirect beneficial owner of 7,344,500 shares held by an entity over which he has voting and dispositive power.
AXSM insider plans a Rule 144 sale of common stock. A notice was filed to sell 31,261 shares of AXSM common stock through Goldman Sachs & Co. LLC on or about 01/07/2026 on the NASD, with an aggregate market value of $5,335,940.09. The filing lists 50,412,640 AXSM common shares outstanding.
The 31,261 shares were originally acquired on 05/27/2016 as compensation via stock options from the issuer, and will be sold through a cashless exercise and same-day sale. Over the past three months, the same seller, Herriot Tabuteau, has reported multiple AXSM common stock sales, including 89,824 shares on 11/03/2025 for $11,902,021.33 and 29,450 shares on 01/06/2026 for $5,074,991.87.
A holder of common stock in AXSM has filed a Rule 144 notice to sell 29,450 shares through Goldman Sachs & Co. LLC, with an aggregate market value of $5,061,866. The shares are expected to be sold on or about January 6, 2026 on the NASD market.
The securities being sold were acquired on May 27, 2016 as compensation in the form of stock options from the issuer, and the planned sale is described as a cashless exercise with same-day sale. The form also lists prior sales over the past three months by Herriot Tabuteau, including individual transactions such as 89,824 shares of common stock sold on November 3, 2025 for gross proceeds of $11,902,021.33 and 41,920 shares sold on January 5, 2026 for $7,227,116.99.
Axsome Therapeutics (AXSM) disclosed insider transactions by its Chief Executive Officer, who is also a Director and 10% Owner. On November 3–5, 2025, the executive exercised stock options and sold the underlying shares pursuant to a pre‑approved Rule 10b5‑1 plan.
Exercises and related sales: on 11/03, 91,705 shares were acquired via option exercise at $8.02 and sold at a weighted average of $132.34 (range $124.16–$137.59). On 11/04, 50,459 shares were exercised at $8.02 and sold at a weighted average of $133.79 (range $131.50–$135.90). On 11/05, 21,775 shares were exercised at $8.02 and sold at a weighted average of $134.49 (range $131.60–$135.49). The filing notes the exercises were necessary due to approaching the options’ 10‑year expiration.
Following the reported transactions, the executive directly held 7,229 shares and indirectly held 7,344,500 shares through an entity over which he has voting and dispositive power.
Axsome Therapeutics (AXSM) reported Q3 2025 results showing strong top-line growth while continuing to invest in commercialization. Total revenues were $170.992M, up from $104.762M a year ago, driven by product sales of $169.784M.
Operating expenses rose to $217.101M as selling, general and administrative costs increased with broader market presence, including advertising of $41.4M in the quarter. The company posted a net loss of $47.229M versus $64.602M last year, narrowing losses as scale improves. Cash and cash equivalents were $325.272M at quarter-end, supporting ongoing commercialization and pipeline work.
Axsome ended the quarter with $595.523M in total liabilities, including a new first‑lien term loan of $120.0M and a revolving credit facility balance of $70.0M under its Blackstone agreement (Term Loans at SOFR + 4.75%, Revolver at SOFR + 4.00%). Shares outstanding were 50,307,834 as of September 30, 2025; 50,412,640 were outstanding as of October 27, 2025.